Angiostomy Cannula Market By Product Type (Cardiac Bypass Cannulas, Peripheral and Vascular Cannulas), By Application (Open-Heart Surgery, Coronary Artery Bypass Grafting, Heart Valve Surgery, Congenital Heart Surgery, ECMO and Extracorporeal Circulation, Thrombus and Embolus Removal), By End User (Hospitals and Cardiac Surgery Centers, Specialty Cardiovascular and ECMO Centers, Ambulatory Surgical Centers), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Angiostomy Cannula Market: Cardiac Surgery Volumes, Thrombus Management and Hospital Procurement Shape Commercial Demand

The Global Angiostomy Cannula Market was valued at an estimated USD 0.42 billion in 2025 and is projected to reach USD 0.67 billion by 2032, expanding at a CAGR of 6.9% during 2026–2032.

 

The angiostomy cannula market consists of single-use devices used to access blood vessels, support cardiopulmonary bypass, enable extracorporeal circulation, and assist in thrombus or embolus removal during cardiac and vascular procedures. In the U.S., these products fall under FDA regulation 21 CFR 870.4210 (product code DWF), which covers cardiovascular catheters and cannulas used in bypass and large-bore vascular access, while other catheter types (e.g., dialysis or neurovascular) are regulated separately.

 

Demand is mainly driven by high volumes of cardiac surgery and extracorporeal support procedures, supported by a global cardiovascular disease burden affecting over 500 million people worldwide. Although cannulas account for a small portion of procedure cost, they are essential consumables, and hospitals prioritize reliability, consistent supply, and ease of use over price due to the risk of flow disruption or procedural complications.

 

An angiostomy cannula typically refers to specialized vascular aspiration and drainage systems such as the FDA-cleared AngioVac System (e.g., K253106), used for extracorporeal removal of thrombi, emboli, and right-heart vegetations during short-duration bypass procedures. The system has Breakthrough Device designation and is being evaluated for expanded indications, including broader vascular access and longer operational use beyond the current 6-hour limit. Competing vascular access and thrombectomy catheters remain Class II devices, with ongoing development focused on low-profile, wire-reinforced designs and improved clot capture efficiency.

 

Cardiac Bypass Cannulas Retain the Largest Product Share

Cardiac bypass cannulas dominated the market with 68.0% share in 2025, valued at USD 285.60 million, and are expected to reach USD 435.17 million by 2032 at a CAGR of 6.2%. They are widely used in cardiopulmonary bypass procedures, where multiple cannulas are required for blood drainage, return, venting, and cardioplegia delivery, making them a core and repeat-use product in cardiac surgery.

These devices are standardized within hospital perfusion systems, meaning surgeons and perfusionists rely on consistent sizes, connectors, and flow performance. As a result, demand is steady but grows more slowly, driven mainly by ongoing surgery volumes and replacement cycles rather than new adoption.

Peripheral and vascular cannulas made up the remaining 32.0% in 2025, worth USD 134.40 million, and are projected to reach USD 234.83 million by 2032 at a faster CAGR of 8.3%. Growth is supported by increasing use in ECMO, minimally invasive procedures, and large-bore vascular access, where flexible and reinforced designs are needed to maintain stable flow.

This segment is expanding as care shifts beyond traditional open-heart surgery settings. Demand is rising for advanced features such as kink resistance, imaging visibility, and atraumatic tips, benefiting manufacturers with broader surgical and extracorporeal product portfolios.

 

Cardiac Surgery Provides the Core Procedure Base

Open cardiac surgery remains the main driver of angiostomy cannula use, as procedures like CABG, valve repair, congenital correction, and aortic surgery often require multiple arterial, venous, and specialty cannulas.

Large surgical volumes support steady demand. The Society of Thoracic Surgeons database covers nearly 10 million procedures across 4,300+ surgeons and about 95% of U.S. adult cardiac surgery. In 2024, Germany reported 103,617 heart operations, Japan recorded 64,047 cardiovascular surgeries, Scotland had 2,298 adult cases, and Australia and New Zealand reported 18,251 cases.

Open-heart surgery was the largest application in 2025, accounting for 24.0% of the market (USD 100.80 million) and is expected to reach USD 150.08 million by 2032 (CAGR 5.9%). Growth is steady but slower as some procedures shift to less invasive transcatheter approaches, though complex and emergency cases continue to support demand.

Coronary artery bypass grafting (CABG) held 22.0% share (USD 92.40 million) in 2025 and is projected to reach USD 141.37 million by 2032 (CAGR 6.3%), driven by multivessel disease and high-risk patients requiring surgical intervention.

Heart valve surgery accounted for 17.0% (USD 71.40 million) in 2025, rising to USD 111.89 million by 2032 (CAGR 6.6%), as surgery remains necessary for complex or unsuitable transcatheter cases.

Congenital heart surgery represented 10.0% (USD 42.00 million) in 2025 and is expected to reach USD 62.31 million by 2032 (CAGR 5.8%), supported by specialized pediatric centers and the need for precision low-diameter cannulas.

 

ECMO and Thrombus Removal Deliver Faster Application Growth

ECMO and extracorporeal circulation accounted for 15.0% of the market in 2025, valued at USD 63.00 million, and are projected to reach USD 119.26 million by 2032 at the fastest application CAGR of 9.5%. ECMO has expanded cannula use beyond operating rooms into intensive-care units, emergency departments and specialist critical-care centres. Unlike short-duration cardiopulmonary bypass, ECMO requires large-bore drainage and return cannulas capable of maintaining stable flow over prolonged support periods.

Expansion of ECMO centres increases demand for multiple cannula sizes, connectors, circuits and insertion kits. Hospitals must stock several configurations because anatomy, target flow and emergency circumstances vary. Long-duration support also raises requirements for blood compatibility, durability and connector integrity, favouring suppliers with complete extracorporeal systems, emergency inventory and clinical training.

Thrombus and embolus removal represented 12.0% of the market in 2025, generating USD 50.40 million, and is forecast to reach USD 85.09 million by 2032 at a CAGR of 7.8%. Large-bore aspiration cannulas are used in selected right-heart, vena cava, pulmonary and peripheral vascular procedures to remove clot without open surgery. Their per-procedure value is higher than standard bypass cannulas because they are sold as part of integrated aspiration and blood-management platforms.

AngioDynamics’ AngioVac system combines aspiration with blood filtration and reinfusion to reduce blood loss. The FDA cleared an updated AngioVac cannula under K253106 in October 2025. AngioDynamics reported USD 11.3 million in fourth-quarter fiscal 2025 mechanical-thrombectomy revenue, up 44.7%, while full-year Med Tech revenue reached USD 126.7 million, up 19.5%. Quarterly thrombectomy revenue reached USD 11.5 million in the third quarter of fiscal 2026, up 17.9%. In the fourth quarter of fiscal 2026, total thrombectomy revenue was USD 11.1 million, with AlphaVac up 38.4% and AngioVac down 15.8%, indicating movement toward newer platforms.

Adoption remains concentrated in specialist centres with advanced imaging, trained teams and large-bore access protocols. This limits customer numbers but increases account value and switching barriers after platform standardization.

 

Engineering, Regulation and Reimbursement Shape Product Selection

Hospitals choose cannulas mainly based on flow efficiency, ease of insertion, and overall reliability. Key design factors include size, wall thickness, tip design, kink resistance, connector strength, and imaging visibility. Different types serve specific roles—venous cannulas support drainage, arterial cannulas reduce vessel trauma, aortic-root devices need stable positioning, and aspiration cannulas require large lumens with safe blood handling.

In the U.S., most cardiovascular cannulas are regulated as Class II devices under the FDA 510(k) pathway, with standards such as ISO 18193 (extracorporeal circulation) and ISO 11658 (blood-contact materials). Recent approvals highlight ongoing innovation, including Medtronic’s MC2/MC2X venous cannulas (K251258, June 2025), LivaNova’s Easyflow range (K250610), and AngioDynamics’ AngioVac clearance in 2025 for higher-value thrombectomy use.

Purchasing decisions are also influenced by safety history. For example, Medtronic issued a Class II recall in October 2024 for select DLP Aortic Root Cannulas, and FDA reports have noted issues such as leakage and flow obstruction in some devices. As a result, hospitals prefer suppliers with strong quality control, reliable connectors, and backup product options.

Reimbursement structures further shape buying behavior. Cannulas are typically bundled into hospital procedure payments under Medicare’s Inpatient Prospective Payment System, encouraging hospitals to prioritize devices that ensure smooth procedures and reduce complications rather than focusing on unit cost.

This trend is reinforced by the U.S. Transforming Episode Accountability Model, launched in January 2026, which includes 721 participants as of July 2026. The bundled-payment approach increases pressure on hospitals to standardize devices and minimize procedural risks.

 

End-User Demand Remains Concentrated in Hospitals and Specialist Centres

Hospitals and cardiac surgery centres accounted for 68.0% of the market in 2025, representing USD 285.60 million, and are projected to reach USD 434.83 million by 2032 at a CAGR of 6.2%. These facilities perform most open-heart, CABG, valve, congenital and aortic procedures and maintain dedicated perfusion departments and multi-size inventories. Group-purchasing and system-wide agreements favour suppliers offering arterial, venous, aortic-root and specialty cannulas through one relationship.

Specialty cardiovascular and ECMO centres held 23.0% of the market in 2025, valued at USD 96.60 million, and are expected to reach USD 177.55 million by 2032 at the fastest end-user CAGR of 9.1%. These centres manage prolonged extracorporeal support and advanced thrombus-removal procedures. Broader cannula requirements, emergency inventory and integrated platforms increase purchasing intensity and the value of clinical support.

Ambulatory surgical centres represented 9.0% of the market in 2025, or USD 37.80 million, and are projected to reach USD 57.62 million by 2032 at a CAGR of 6.2%. Their use is concentrated in lower-complexity vascular procedures that do not require full cardiopulmonary bypass or prolonged support. Growth depends on the continued migration of suitable procedures into outpatient settings and products that provide reliable performance without complex supporting inventories.

 

Regional Demand Reflects Procedure Capacity and Procurement Structure

North America led the market with a 41.0% share in 2025, valued at USD 172.20 million, and is projected to reach USD 259.29 million by 2032 at a CAGR of 6.0%. The region benefits from advanced cardiac surgery infrastructure and strong use of ECMO and thrombectomy systems. AngioDynamics reported USD 67.5 million in U.S. Q4 FY2025 sales vs USD 12.7 million internationally, highlighting strong domestic demand for premium platforms.

Europe held 27.0% share (USD 113.40 million in 2025) and is expected to reach USD 171.52 million by 2032 at a CAGR of 6.1%. Demand is supported by established cardiac surgery programs in Germany and the UK, though procurement is influenced by centralized tenders and supply constraints, including NHS reports of shortages across 178 perfusion-cannula products.

Asia-Pacific accounted for 23.0% share (USD 96.60 million in 2025) and is projected to reach USD 176.88 million by 2032, growing fastest at a CAGR of 9.0%. Growth is driven by rising cardiac surgery volumes, ECMO expansion, and broader access to advanced procedures, with Japan alone reporting 64,047 cardiovascular surgeries in 2024.

Latin America held 5.0% share (USD 21.00 million in 2025) and is expected to reach USD 34.84 million by 2032 at a CAGR of 7.5%, driven mainly by major cardiac hospitals in Brazil, Mexico, Argentina, and Colombia, where access depends on tenders and distribution networks.

The Middle East and Africa accounted for 4.0% share (USD 16.80 million in 2025) and are projected to reach USD 27.47 million by 2032 at a CAGR of 7.3%. Growth is supported by Gulf investment in advanced cardiac care and ECMO, while limited specialist capacity and infrastructure remain key constraints in parts of Africa.

 

Competitive Positioning Depends on the Complete Procedural Platform

Competition includes Medtronic, LivaNova/Sorin, Edwards Lifesciences and AngioDynamics. In cardiopulmonary bypass, strength comes from portfolio breadth, compatibility with established circuits, clinician familiarity and access to hospital contracts. Suppliers offering arterial, venous, aortic-root and specialty cannulas can simplify procurement and support system-wide standardization.

Aspiration thrombectomy is more platform-driven, combining cannulas with pumps, filters, blood-return components and procedural support. These integrated systems require greater training and service but create stronger switching barriers after adoption. Competitive investment is therefore shifting toward faster-growing areas: peripheral and vascular cannulas at an 8.3% CAGR, ECMO applications at 9.5%, specialty cardiovascular and ECMO centres at 9.1%, and Asia-Pacific at 9.0%.

 

Analyst Perspective

The market is shifting from basic surgical consumables to a mix of high-volume perfusion products and advanced extracorporeal and aspiration systems. Cardiac bypass cannulas remain the largest segment, growing from USD 285.60 million in 2025 to USD 435.17 million by 2032, while peripheral and vascular cannulas are expanding faster due to wider use in minimally invasive and ECMO procedures.

Open-heart surgery and CABG still drive the highest procedure volumes, but ECMO and extracorporeal circulation are the fastest-growing applications, increasing from USD 63.00 million to USD 119.26 million at a 9.5% CAGR. Specialty cardiovascular and ECMO centres are also expanding more quickly than general hospitals, reaching USD 177.55 million by 2032.

Regionally, North America remains the largest market, while Asia-Pacific shows the fastest growth. Competition is increasingly focused on reliable flow performance, integrated systems, and supply stability rather than price alone. Overall, the market is expected to grow from USD 0.42 billion in 2025 to USD 0.67 billion by 2032 at a CAGR of 6.9%.

 

Angiostomy Cannula Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 420.00 Million
Revenue Forecast in 2032	USD 670.00 Million
Overall Growth Rate	CAGR of 6.9% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Cardiac Bypass Cannulas, Peripheral and Vascular Cannulas
By Application	Open-Heart Surgery, Coronary Artery Bypass Grafting, Heart Valve Surgery, Congenital Heart Surgery, ECMO and Extracorporeal Circulation, Thrombus and Embolus Removal
By End User	Hospitals and Cardiac Surgery Centers, Specialty Cardiovascular and ECMO Centers, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising cardiac surgery volumes, expanding ECMO capacity, growing use of minimally invasive thrombus-removal procedures, and demand for reliable large-bore vascular access devices
Customization Option	Available upon request